Compare Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Global ex-US Real Estate Index Fd ETF vs Zoetis Inc — how do they compare? Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.51, while Zoetis Inc trades at $73.86 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and Vanguard Global ex-US Real Estate Index Fd ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| VNQI | ZTS | |
|---|---|---|
52-Week High | $50.76 | $156.76 |
52-Week Low | $43.26 | $71.91 |
Market Cap | — | $31.14B |
Sector | — | Health |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.77, up 0.46% with a bullish technical signal from moving averages. The ETF provides diversified international real estate exposure across 30+ countries outside the U.S., featuring a low expense ratio and higher dividend yield compared to domestic REIT ETFs. Recent news highlights ongoing comparisons with competing real estate funds, with VNQI's international diversification being a key differentiator.
The outlook for VNQI remains positive given its global real estate diversification benefits and income-oriented profile. Key opportunities include exposure to growing international property markets and attractive dividend yield, while risks involve currency fluctuations, geopolitical uncertainties, and potential underperformance relative to U.S. real estate markets. The ETF's low-cost structure supports long-term total return potential for investors seeking international real estate exposure.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
